Ready to start planning your care? Call us at 833-347-1665 to make an appointment.

Sloan Kettering Institute
Research
- - Changing how the world understands and treats cancer
    Our scientists pursue every aspect of cancer research—from exploring the biology of genes and cells, to developing immune-based treatments, uncovering the causes of metastasis, and more.
- - Programs & Centers
  - Sloan Kettering Institute
    Pursuing basic and translational research across 9 programs and 100+ labs
  - Memorial Hospital research
    Focusing on clinical cancer research and population health
  - Human Oncology & Pathogenesis Program (HOPP)
    Bridging the lab and the clinic through translational research
  - Collaborative research centers
    Fostering interdisciplinary collaborations between laboratory scientists and clinicians
  - Extramural collaborations
    Partnering with other academic and research institutions
- - Research at MSK
  - Our research impact
  - Research topics
  - Core facilities & resources
    Offering state-of-the-art resources for our researchers
  - Find a researcher or lab
  - Education & training programs
Education & Training
- - Training the next generation of clinicians and scientists
    Our highly-specialized educational programs shape leaders to be at the forefront of cancer care and research.
- - For Research
  - Postdoctoral training
  - Gerstner Sloan Kettering Graduate School of Biomedical Sciences
    Offering a curriculum with a focus on cancer
  - PhD & MD/PhD programs
  - MSK Bridge program
    Connecting college seniors to future careers in biomedicine
  - High school & undergraduate summer programs
Careers
MSK Direct
Locations & Language
In the U.S.
Outside of the U.S.

Make an Appointment
Back
Make an Appointment
- - We’re here for you.
    Make an appointment
    New patient
    Current patient
    Speak to a care advisor
    Adults: 833-920-3234
    Monday through Friday, 8 a.m. to 6 p.m. (Eastern time)
    Children & Teens: 833-MSK-KIDS
    Monday through Friday, 9 a.m. to 5 p.m. (Eastern time)
- - Becoming A Patient
  - How to get started
  - Insurance & financial assistance
  - Preparing for your first appointment
  - Meet our doctors
  - Explore our locations
Refer a Patient
Back
Refer a Patient
- - Partner with us to treat your patient’s cancer.
    Refer a patient
    CALL OUR DEDICATED CLINICIAN ACCESS NUMBER
    833-315-2722
    Monday to Friday, 8 a.m. to 6 p.m. (Eastern time)
- - Clinical Resources
  - Our doctors
  - Physician relations
  - Clinical updates & insights
  - Prediction tools
  - Clinical trials
  - Continuing medical education (CME)
Learn About Cancer & Treatment
Back
Learn About Cancer & Treatment
- - We treat every type of cancer, including the most important one: yours.
    With cancer, where you get treated first matters. From diagnosis to treatment, our experts provide the care and support you need, when you need it.
- - Adults
  - Cancers & conditions
  - Risk assessment & screening
  - Diagnosis & treatment
  - Clinical trials
  - Children & Teens
  - Cancers & conditions
  - Diagnosis & treatment
  - Clinical trials
- - Support, Services & Programs
  - For adults
  - For children & teens
  - For caregivers
  - Adolescents & young adult (AYA) program
  - Patient & caregiver education library
  - Cancer News & Discoveries
  - Read the latest
  - Sign up for our newsletter
About Us
Back
About Us
- - Our mission: Ending cancer for life.
    Memorial Sloan Kettering was founded in 1884, and today is a world leader in patient care, research, and educational programs.
- - About Us
  - Our mission, vision & core values
  - Leadership
  - History
  - Equality, diversity & inclusion
  - Annual report
  - Give to MSK
  - For the Media
  - Media inquiries
  - News releases
  - News & information
- - Have Questions?
  - Contact us
  - Plan Your Visit
  - Explore our locations
  - Directions
  - Visitor policy
Patient Portal: MyMSK
Donate Now
- Sloan Kettering Institute
- Research
  Back
  Research
  - Programs & Centers
    Sloan Kettering Institute
    Pursuing basic and translational research across 9 programs and 100+ labs
    Memorial Hospital research
    Focusing on clinical cancer research and population health
    Human Oncology & Pathogenesis Program (HOPP)
    Bridging the lab and the clinic through translational research
    Collaborative research centers
    Fostering interdisciplinary collaborations between laboratory scientists and clinicians
    Extramural collaborations
    Partnering with other academic and research institutions
  - Research at MSK
    Our research impact
    Research topics
    Core facilities & resources
    Offering state-of-the-art resources for our researchers
    Find a researcher or lab
    Education & training programs
- Education & Training
  Back
  Education & Training
  - For Healthcare
    Graduate medical education (GME)
    Medical student opportunities
    Continuing medical education (CME)
    Continuing nursing education (CNE)
    Academic departments & divisions
    Explore all programs
  - For Research
    Postdoctoral training
    Gerstner Sloan Kettering Graduate School of Biomedical Sciences
    Offering a curriculum with a focus on cancer
    PhD & MD/PhD programs
    MSK Bridge program
    Connecting college seniors to future careers in biomedicine
    High school & undergraduate summer programs
- Careers
- MSK Direct
- Locations & Language
  Back
  Locations & Language
  In the U.S.
  English
  Español
  Pусский
  Outside of the U.S.
  العَرَبِيَّة
  Deutsch
  English
  Español
  한국어
  עִבְרִית
  Italiano
  Portugês
  Pу́сский
  Türkçe
  中文

Miguel A. Miranda-Roman, PhD

Post-Doctoral Fellow at Boehringer Ingelheim in Ridgefield, CT

Share

Share

Miguel Miranda-Roman

Email

[email protected]

Dissertation

Overcoming Resistance to MEK Inhibitor Treatment in NF1-Deficient MPNST

Mentor

Ping Chi, MD, PhD

Start Year

2015

End Year

2023

Education

BS, University of Puerto Rico, Rio Piedras

Fellowships

Beatrice P.K. Palestin Fellowship (2016-2017)
DoD Peer Reviewed Cancer Horizon Award (2019-21)

Publications

Yan J, Chen Y, Patel AJ, Warda S, Lee CJ, Nixon BG, Wong EW, Miranda-Román MA, Yang N, Wang Y, Pachai MR, Sher J, Giff E, Tang F, Khurana E, Singer S, Liu Y, Galbo PM Jr, Maag JL, Koche RP, Zheng D, Antonescu C, Deng L, Li M, Chen Y, Chi P. Tumor-intrinsic PRC2 inactivation drives a context-dependent immune-desert microenvironment and is sensitized by immunogenic therapeutic viruses. J Clin Invest. (2022)

Patel AJ, Warda S, Maag JLV, Misra R, Miranda-Roman MA, Pachai MR, Lee CJ, Li D, Wang N, Bayshtok G, Fishinevich E, Meng Y, Wong EWP, Yan J, Giff E, Pappalardi MB, McCabe MT, Fletcher JA, Rudin CM, Chandarlapaty S, Scandura JM, Koche RP, Glass JL, Antonescu CR, Zheng D, Chen Y, Chi P. PRC2 Inactivating Mutations in Cancer Enhance Cytotoxic Response to DNMT1 Targeted Therapy via Enhanced Viral Mimicry. Cancer Discov. (2022)

Lopez A, Reyna DE, Gitego N, Kopp F, Zhou H, Miranda-Roman MA. Nordstrøm LU, Narayanagari SR, Chi P, Vilar E, Tsirigos A, Gavathiotis E. (2022) Co-targeting of BAX and BCL-XL proteins broadly overcomes resistance to apoptosis in cancer. Nat Commun. 13

Rivera-Díaz M, Miranda-Román MA, Soto D, Quintero-Aguilo M, Ortiz-Zuazaga H, Marcos-Martinez MJ, Vivas-Mejía PE. (2014) MicroRNA-27a distinguishes glioblastoma multiforme from diffuse and anaplastic astrocytomas and has prognostic value. Am J Cancer Res., 5, 201-18. PMCID: PMC4300691.